BioNTech SE (WBO:BNTX)
€ 108.9 0.6 (0.55%) Market Cap: 26.09 Bil Enterprise Value: 9.63 Bil PE Ratio: 0 PB Ratio: 1.29 GF Score: 62/100

BioNTech SE - Special Call Transcript

Apr 23, 2020 / 12:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioNTech's COVID-19 vaccine program update call. (Operator Instructions) I must advise you that this call is being recorded today on Thursday, the 23rd of April 2020. I would now like to hand the call over to the Vice President, Investor Relations and Business Strategy, Sylke Maas. Please go ahead.

Sylke Maas
BioNTech SE - VP of IR and Business Strategy

Thank you for joining us today for BioNTech's COVID-19 vaccine program update call. Before we start, I encourage you to view the slides for the webcast as well as the press release issued yesterday, April 22, both of which are accessible on our website in the Investors section.

As shown on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, BioNTech's efforts to combat COVID-19; the planned next steps in BioNTech's Project Lightspeed; the timing to initiate clinical trials for BNT162 in Germany; collaborations between BioNTech and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot